You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclosporine
Accession NumberDB00091  (BTD00003, BIOD00003)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. Cyclosporine is produced as a metabolite by the fungus species Cordyceps militaris. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Structure
Thumb
Synonyms
Ciclosporin
Ciclosporina
Ciclosporine
Ciclosporinum
CsA
CyA
Cyclosporin
Cyclosporin A
External Identifiers
  • Antibiotic S 7481F1
  • Antibiotic S-7481F1
  • NSC-290193
  • SANG-35
  • SDZ-OXL-400
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyclosporinecapsule25 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Neoralsolution100 mg/mLoralNovartis Pharmaceuticals Corporation1995-07-14Not applicableUs
Neoralcapsule, liquid filled25 mg/1oralNovartis Pharmaceuticals Corporation1995-07-14Not applicableUs
Neoralcapsule, liquid filled25 mg/1oralCardinal Health1995-07-14Not applicableUs
Neoralcapsule, liquid filled100 mg/1oralNovartis Pharmaceuticals Corporation1995-07-14Not applicableUs
Neoral 100mgcapsule100 mgoralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Neoral 10mgcapsule10 mgoralNovartis Pharmaceuticals Canada Inc1998-10-02Not applicableCanada
Neoral 25mgcapsule25 mgoralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Neoral 50mgcapsule50 mgoralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Neoral Oral Solution 100mg/mlsolution100 mgoralNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Restasisemulsion.5 mg/mLophthalmicAllergan, Inc.2003-04-01Not applicableUs
Restasisemulsion0.05 %ophthalmicAllergan Inc2010-09-29Not applicableCanada
Restasisemulsion.5 mg/mLophthalmicPhysicians Total Care, Inc.2009-03-27Not applicableUs
Sandimmunecapsule, liquid filled100 mg/1oralNovartis Pharmaceuticals Corporation1990-03-02Not applicableUs
Sandimmuneinjection50 mg/mLintravenousNovartis Pharmaceuticals Corporation1983-11-14Not applicableUs
Sandimmunesolution100 mg/mLoralNovartis Pharmaceuticals Corporation1983-11-14Not applicableUs
Sandimmunecapsule, liquid filled25 mg/1oralNovartis Pharmaceuticals Corporation1990-03-02Not applicableUs
Sandimmune Cap 50mgcapsule50 mgoralSandoz Canada Inc1991-12-311996-11-14Canada
Sandimmune IV 50mg/mlliquid50 mgintravenousNovartis Pharmaceuticals Canada Inc1984-12-31Not applicableCanada
Sandimmune Oral Sol 100mg/mlliquid100 mgoralSandoz Canada Inc1984-12-311997-04-15Canada
Sandimmune Soft Gelatin Cap 100mgcapsule100 mgoralSandoz Canada Inc1988-12-311997-04-15Canada
Sandimmune Soft Gelatine Cap 25mgcapsule25 mgoralSandoz Canada Inc1988-12-311997-04-15Canada
Sandoz Cyclosporinecapsule100 mgoralSandoz Canada Incorporated2001-12-27Not applicableCanada
Sandoz Cyclosporinecapsule25 mgoralSandoz Canada Incorporated2005-05-16Not applicableCanada
Sandoz Cyclosporinecapsule50 mgoralSandoz Canada Incorporated2006-10-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cyclosporine Oral Solutionsolution100 mgoralApotex Inc2002-07-30Not applicableCanada
Cyclosporinecapsule, liquid filled100 mg/1oralCardinal Health2010-09-01Not applicableUs
Cyclosporinecapsule, liquid filled25 mg/1oralActavis Pharma, Inc.2008-12-01Not applicableUs
Cyclosporinesolution100 mg/mLoralIVAX Pharmaceuticals, Inc.2005-03-29Not applicableUs
Cyclosporinecapsule, liquid filled25 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Cyclosporinecapsule, liquid filled100 mg/1oralPhysicians Total Care, Inc.2011-02-10Not applicableUs
Cyclosporinesolution100 mg/mLoralMorton Grove Pharmaceuticals, Inc.2005-02-09Not applicableUs
Cyclosporinecapsule, liquid filled100 mg/1oralActavis Pharma, Inc.2008-12-01Not applicableUs
Cyclosporinecapsule, liquid filled100 mg/1oralAmerican Health Packaging2015-03-30Not applicableUs
Cyclosporinecapsule25 mg/1oralEon Labs, Inc.2000-01-13Not applicableUs
Cyclosporinecapsule, gelatin coated25 mg/1oralApotex Corp.2002-05-29Not applicableUs
Cyclosporinesolution100 mg/mLoralActavis Pharma, Inc.2008-12-01Not applicableUs
Cyclosporinecapsule100 mg/1oralAmerican Health Packaging2009-12-112015-12-29Us
Cyclosporinecapsule100 mg/1oralEon Labs, Inc.2000-01-13Not applicableUs
Cyclosporinecapsule, gelatin coated100 mg/1oralApotex Corp.2002-05-29Not applicableUs
Cyclosporinecapsule, liquid filled100 mg/1oralPhysicians Total Care, Inc.2006-02-10Not applicableUs
Cyclosporineinjection, solution50 mg/mLintravenousPerrigo Company2003-10-07Not applicableUs
Cyclosporine Modifiedcapsule, liquid filled100 mg/1oralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Cyclosporine Modifiedcapsule, liquid filled25 mg/1oralIVAX Pharmaceuticals, Inc.2005-03-29Not applicableUs
Cyclosporine Modifiedcapsule, liquid filled25 mg/1oralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Cyclosporine Modifiedcapsule, liquid filled50 mg/1oralIVAX Pharmaceuticals, Inc.2005-04-28Not applicableUs
Cyclosporine Modifiedcapsule, liquid filled50 mg/1oralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Cyclosporine Modifiedcapsule, liquid filled100 mg/1oralIVAX Pharmaceuticals, Inc.2005-03-29Not applicableUs
Gengrafcapsule25 mg/1oralAbb Vie Inc.2010-05-24Not applicableUs
Gengrafsolution100 mg/mLoralAbb Vie Inc.2010-05-25Not applicableUs
Gengrafcapsule100 mg/1oralAbb Vie Inc.2010-05-24Not applicableUs
Gengrafcapsule100 mg/1oralCardinal Health2010-05-24Not applicableUs
Gengrafcapsule25 mg/1oralAbb Vie Inc.2010-05-24Not applicableUs
Gengrafcapsule25 mg/1oralCardinal Health2010-05-24Not applicableUs
Gengrafcapsule100 mg/1oralAbb Vie Inc.2010-05-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SangcyaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII83HN0GTJ6D
CAS number59865-13-3
WeightAverage: 1202.635
Monoisotopic: 1201.841368058
Chemical FormulaC62H111N11O12
InChI KeyPMATZTZNYRCHOR-CGLBZJNRSA-N
InChI
InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
IUPAC Name
SMILES
CC[C@@H]1NC(=O)[[email protected]]([[email protected]](O)[[email protected]](C)C\C=C\C)N(C)C(=O)[[email protected]](C(C)C)N(C)C(=O)[[email protected]](CC(C)C)N(C)C(=O)[[email protected]](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[[email protected]](C)NC(=O)[[email protected]](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[[email protected]](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
KingdomOrganic compounds
Super ClassOrganic Polymers
ClassPolypeptides
Sub ClassNot Available
Direct ParentPolypeptides
Alternative Parents
Substituents
  • Polypeptide
  • Cyclosporin-backbone
  • Cyclic peptoid/peptide
  • Macrolactam
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
  • Non-ribosomal peptide/polyketide hybrids (C05086 )
Pharmacology
IndicationFor treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.
PharmacodynamicsUsed in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2.
Mechanism of actionCyclosporine binds to cyclophilin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release. In ophthalmic applications, the precise mechanism of action is not known. Cyclosporine emulsion is thought to act as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
Related Articles
AbsorptionThe absorption of cyclosporine from the gastrointestinal tract is incomplete and variable. The extent of absorption is dependent on the individual patient, the patient population, and the formulation. The absolute bioavailability of cyclosproine administered as Sandimmune® is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. Compared to an intravenous infusion, the absolute bioavailability of the oral solution is approximately 30% based upon the results in 2 patients. The cyclosporine capsules and oral solution are bioequivalent. The time of peak blood concentrations (Tmax) following oral administration of cyclosporine [modified] ranged from 1.5 - 2.0 hours.
Volume of distribution

The steady state volume of distribution during intravenous dosing has been reported as 3 to 5 L/kg in solid organ transplant recipients. Cyclosporine is excreted in human milk.

Protein bindingIn the plasma, approximately 90% is bound to proteins, primarily lipoproteins. In blood, the distribution is concentration dependent. Approximately 33% to 47% is in plasma, 4% to 9% in lymphocytes, 5% to 12% in granulocytes, and 41% to 58% in erythrocytes.
Metabolism

Hepatic, extensively metabolized by the cytochrome P450 3A enzyme system in the liver. It is also metabolized in the gastrointestinal tract and kidney to a lesser degree. The metabolites are significantly less potent than the parent compound. The major metabolites (M1, M9, and M4N) result from oxidation at the 1-beta, 9-gamma, and 4-N-demethylated positions, respectively.

SubstrateEnzymesProduct
Cyclosporine
Metabolite AM1Details
Route of eliminationElimination is primarily biliary with only 6% of the dose (parent drug and metabolites) excreted in the urine. Only 0.1% of the dose is excreted in the urine as unchanged drug.
Half lifeBiphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.
Clearance

Following intravenous administration, the blood clearance of cyclosporine (assay: HPLC) is approximately 5 to 7 mL/min/kg in adult recipients of renal or liver allografts. Blood cyclosporine clearance appears to be slightly slower in cardiac transplant patients. The following are clearance parameters (CL/F) for select patient populations:

  • 593 ± 204 mL/min [De novo renal transplant patients, 597±174 mg/day]
  • 492 ± 140 mL/min [Stable renal transplant patients, 344±122 mg/day]
  • 577 ± 309 mL/min [De novo liver transplant, 458±190 mg/day]
  • 613 ± 196 mL/min [De novo rheumatoid arthritis, 182±55.6 mg/day]
  • 723 ± 186 mL/min [De novo psoriasis, 189±69.8 mg/day]
  • 285 ± 94 mL/min [Stable Liver Transplant, Age 2 – 8, Dosed T.I.D 101±25 mg/day]
  • 378 ± 80 mL/min [Stable Liver Transplant, Age 8 – 15, Dosed B.I.D 188±55 mg/day]
  • 171 mL/min [Stable liver transplant, Age 3, Dosed B.I.D 120 mg/day]
  • 328 ± 121 mL/min [Stable liver transplant, Age 8 – 15, Dosed B.I.D 158±55 mg/day]
  • 418 ± 143 mL/min [Stable renal transplant, Age 7 – 15, Dosed B.I.D 328±83 mg/day]
ToxicityThe oral LD50 is 2329 mg/kg in mice, 1480 mg/kg in rats, and > 1000 mg/kg in rabbits. The I.V. LD50 is 148 mg/kg in mice, 104 mg/kg in rats, and 46 mg/kg in rabbits.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Cytotoxic T-lymphocyte protein 4
Gene symbol: CTLA4
UniProt: P16410
rs231775 Not AvailableA AlleleGingival overgrowth, periodontal disease18021981
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8727
Blood Brain Barrier-0.9659
Caco-2 permeable-0.6994
P-glycoprotein substrateSubstrate0.8463
P-glycoprotein inhibitor IInhibitor0.8685
P-glycoprotein inhibitor IINon-inhibitor0.5992
Renal organic cation transporterNon-inhibitor0.9485
CYP450 2C9 substrateNon-substrate0.8628
CYP450 2D6 substrateNon-substrate0.8823
CYP450 3A4 substrateSubstrate0.6407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.923
CYP450 2D6 inhibitorNon-inhibitor0.9265
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.6112
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9968
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8948
BiodegradationNot ready biodegradable0.9244
Rat acute toxicity2.8788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9815
hERG inhibition (predictor II)Non-inhibitor0.9214
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pliva inc
  • Sandoz inc
  • Abbott laboratories
  • Novartis pharmaceuticals corp
  • Allergan inc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmaforce inc
  • Novex pharma
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
Packagers
Dosage forms
FormRouteStrength
Capsule, gelatin coatedoral100 mg/1
Capsule, gelatin coatedoral25 mg/1
Injection, solutionintravenous50 mg/mL
Capsule, liquid filledoral50 mg/1
Capsuleoral100 mg/1
Capsuleoral25 mg/1
Solutionoral100 mg/mL
Capsuleoral100 mg
Capsuleoral10 mg
Capsuleoral25 mg
Capsuleoral50 mg
Solutionoral100 mg
Emulsionophthalmic.5 mg/mL
Emulsionophthalmic0.05 %
Capsule, liquid filledoral100 mg/1
Capsule, liquid filledoral25 mg/1
Injectionintravenous50 mg/mL
Liquidintravenous50 mg
Liquidoral100 mg
Prices
Unit descriptionCostUnit
SandIMMUNE 100 mg/ml Solution 50ml Bottle499.62USD bottle
Neoral 100 mg/ml Solution 50ml Bottle346.14USD bottle
CycloSPORINE Modified 100 mg/ml Solution 50ml Bottle311.53USD bottle
SandIMMUNE 30 100 mg capsule Box308.69USD box
Restasis 30 0.05% Emulsion 1 Box = 30 Containers205.99USD box
Neoral 30 100 mg capsule Box190.54USD box
CycloSPORINE Modified 30 100 mg capsule Box171.48USD box
Gengraf 30 100 mg capsule Box159.94USD box
SandIMMUNE 30 25 mg capsule Box77.33USD box
Neoral 30 25 mg capsule Box47.69USD box
SandIMMUNE 50 mg/ml Solution 5ml Ampule46.38USD ampule
Gengraf 30 25 mg capsule Box42.99USD box
CycloSPORINE Modified 30 25 mg capsule Box42.9USD box
Cyclosporine a powder25.2USD g
Sandimmune 100 mg capsule9.89USD capsule
Sandimmune 50 mg/ml ampul7.71USD ml
Cyclosporine 100 mg capsule6.46USD capsule
Neoral 100 mg gelatn capsule6.11USD capsule
Cyclosporine 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg capsule5.49USD capsule
Cyclosporine 50 mg/ml amp5.45USD ml
Cyclosporine 50 mg/ml vial5.28USD ml
Gengraf 100 mg capsule5.28USD capsule
Restasis 0.05% eye emulsion4.49USD each
Cyclosporine 50 mg softgel2.74USD softgel capsule
Sandimmune 25 mg capsule2.48USD capsule
Cyclosporine 25 mg capsule1.56USD capsule
Neoral 25 mg gelatin capsule1.53USD capsule
Cyclosporine 25 mg softgel1.38USD softgel capsule
Gengraf 25 mg capsule1.32USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1332150 No1994-09-272011-09-27Canada
CA2108018 No2003-04-152012-04-16Canada
US4839342 No1992-08-022009-08-02Us
US5985321 No1994-09-262014-09-26Us
US8629111 No2004-08-272024-08-27Us
US8633162 No2004-08-272024-08-27Us
US8642556 No2004-08-272024-08-27Us
US8648048 No2004-08-272024-08-27Us
US8685930 No2004-08-272024-08-27Us
US9248191 No2004-08-272024-08-27Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point148-151 °CNot Available
Caco2 permeability-6.05ADME Research, USCD
Predicted Properties
PropertyValueSource
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Hans Dietl, “Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production.” U.S. Patent US5527537, issued October, 1990.

US5527537
General References
  1. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841-5. [PubMed:8196726 ]
  2. Husi H, Schorgendorfer K, Stempfer G, Taylor P, Walkinshaw MD: Prediction of substrate-specific pockets in cyclosporin synthetase. FEBS Lett. 1997 Sep 15;414(3):532-6. [PubMed:9323029 ]
  3. Link [Link]
External Links
ATC CodesS01XA18L04AD01
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (176 KB)
MSDSDownload (83.2 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Cyclosporine can be increased when it is combined with 1,10-Phenanthroline.
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Cyclosporine can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Cyclosporine can be decreased when combined with 2-mercaptobenzothiazole.
3,4-DichloroisocoumarinThe serum concentration of Cyclosporine can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Cyclosporine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Cyclosporine.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Cyclosporine.
AceclofenacAceclofenac may increase the nephrotoxic activities of Cyclosporine.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Cyclosporine.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Cyclosporine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Cyclosporine.
AcetaminophenThe serum concentration of Cyclosporine can be increased when it is combined with Acetaminophen.
AcetazolamideThe serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Cyclosporine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Cyclosporine.
AdalimumabThe serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.
AdapaleneAdapalene may increase the nephrotoxic activities of Cyclosporine.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Cyclosporine.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Cyclosporine.
AfatinibThe serum concentration of Cyclosporine can be increased when it is combined with Afatinib.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Cyclosporine.
AlbendazoleThe serum concentration of Cyclosporine can be increased when it is combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Cyclosporine.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Cyclosporine.
AlectinibThe serum concentration of Cyclosporine can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Cyclosporine.
AlfentanilThe serum concentration of Cyclosporine can be increased when it is combined with Alfentanil.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Cyclosporine.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Cyclosporine.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Cyclosporine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cyclosporine.
AlogliptinThe serum concentration of Cyclosporine can be increased when it is combined with Alogliptin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Cyclosporine.
AlosetronThe metabolism of Alosetron can be decreased when combined with Cyclosporine.
Alpha-1-proteinase inhibitorThe serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Cyclosporine.
AmantadineThe serum concentration of Cyclosporine can be increased when it is combined with Amantadine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Cyclosporine.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Cyclosporine.
AmikacinAmikacin may increase the nephrotoxic activities of Cyclosporine.
AmilorideAmiloride may increase the hyperkalemic activities of Cyclosporine.
Aminohippuric acidThe serum concentration of Cyclosporine can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Cyclosporine.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Cyclosporine.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Cyclosporine.
AmiodaroneThe serum concentration of Cyclosporine can be decreased when it is combined with Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Cyclosporine.
AmitriptylineThe serum concentration of Cyclosporine can be increased when it is combined with Amitriptyline.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Cyclosporine.
AmlodipineThe serum concentration of Cyclosporine can be increased when it is combined with Amlodipine.
AmobarbitalThe metabolism of Cyclosporine can be increased when combined with Amobarbital.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Cyclosporine.
AmorolfineThe metabolism of Cyclosporine can be decreased when combined with Amorolfine.
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Cyclosporine.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cyclosporine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Cyclosporine.
AmprenavirThe serum concentration of Cyclosporine can be decreased when it is combined with Amprenavir.
AmrinoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Amrinone.
AmsacrineThe serum concentration of Cyclosporine can be increased when it is combined with Amsacrine.
AN2690The metabolism of Cyclosporine can be decreased when combined with AN2690.
AnidulafunginThe metabolism of Cyclosporine can be decreased when combined with Anidulafungin.
AntipyrineAntipyrine may increase the nephrotoxic activities of Cyclosporine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Cyclosporine.
Antithrombin III humanThe serum concentration of Cyclosporine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Cyclosporine.
ApremilastApremilast may increase the nephrotoxic activities of Cyclosporine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Cyclosporine.
AprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Cyclosporine.
AprotininThe serum concentration of Cyclosporine can be increased when it is combined with Aprotinin.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Cyclosporine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Cyclosporine.
ArgatrobanThe serum concentration of Cyclosporine can be increased when it is combined with Argatroban.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Cyclosporine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.
ArmodafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cyclosporine.
ArtemetherThe metabolism of Cyclosporine can be decreased when combined with Artemether.
AsenapineThe metabolism of Asenapine can be decreased when combined with Cyclosporine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Cyclosporine.
AstemizoleThe serum concentration of Cyclosporine can be increased when it is combined with Astemizole.
AsunaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Asunaprevir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Cyclosporine.
AtazanavirThe serum concentration of Cyclosporine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Cyclosporine.
AtenololThe serum concentration of Cyclosporine can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Cyclosporine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.
AvanafilThe metabolism of Avanafil can be decreased when combined with Cyclosporine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Cyclosporine.
AzapropazoneAzapropazone may increase the nephrotoxic activities of Cyclosporine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Cyclosporine.
AzelastineThe serum concentration of Cyclosporine can be increased when it is combined with Azelastine.
AzelnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azelnidipine.
Azilsartan medoxomilAzilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine.
AzimilideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azimilide.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Cyclosporine.
AzithromycinThe serum concentration of Cyclosporine can be increased when it is combined with Azithromycin.
Bafilomycin A1The metabolism of Cyclosporine can be decreased when combined with Bafilomycin A1.
BalsalazideBalsalazide may increase the nephrotoxic activities of Cyclosporine.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Cyclosporine.
BarbitalThe metabolism of Cyclosporine can be increased when combined with Barbital.
BarnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Barnidipine.
BatimastatThe serum concentration of Cyclosporine can be increased when it is combined with Batimastat.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Cyclosporine.
BenazeprilThe serum concentration of Cyclosporine can be increased when it is combined with Benazepril.
BenidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Benidipine.
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Cyclosporine.
BenzamidineThe serum concentration of Cyclosporine can be increased when it is combined with Benzamidine.
BenzocaineThe serum concentration of Cyclosporine can be increased when it is combined with Benzocaine.
Benzoic AcidThe metabolism of Cyclosporine can be decreased when combined with Benzoic Acid.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Cyclosporine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Cyclosporine.
BepridilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.
BepridilThe serum concentration of Cyclosporine can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Cyclosporine.
BexaroteneThe serum concentration of Cyclosporine can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Cyclosporine.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Cyclosporine.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Cyclosporine.
BifonazoleThe metabolism of Cyclosporine can be decreased when combined with Bifonazole.
BiperidenThe serum concentration of Cyclosporine can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cyclosporine.
BivalirudinThe serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Cyclosporine can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Cyclosporine.
BortezomibThe metabolism of Cyclosporine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Cyclosporine.
BosentanThe serum concentration of Cyclosporine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cyclosporine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Cyclosporine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Cyclosporine.
BromfenacBromfenac may increase the nephrotoxic activities of Cyclosporine.
BromocriptineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Cyclosporine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Cyclosporine.
BudesonideThe metabolism of Budesonide can be decreased when combined with Cyclosporine.
BumetanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Cyclosporine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Cyclosporine.
BuprenorphineThe serum concentration of Cyclosporine can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Cyclosporine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Cyclosporine.
BuspironeThe serum concentration of Cyclosporine can be increased when it is combined with Buspirone.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Cyclosporine.
ButenafineThe metabolism of Cyclosporine can be decreased when combined with Butenafine.
ButoconazoleThe metabolism of Cyclosporine can be decreased when combined with Butoconazole.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.
CabazitaxelThe serum concentration of Cyclosporine can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Cyclosporine.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Cyclosporine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Cyclosporine.
CaffeineThe serum concentration of Cyclosporine can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Cyclosporine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Cyclosporine.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Cyclosporine.
CanagliflozinThe serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.
CandesartanCandesartan may increase the hyperkalemic activities of Cyclosporine.
CandesartanThe metabolism of Candesartan can be decreased when combined with Cyclosporine.
CandicidinThe metabolism of Cyclosporine can be decreased when combined with Candicidin.
CandoxatrilThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Cyclosporine can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Cyclosporine.
CarbamazepineThe serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Cyclosporine.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Cyclosporine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Cyclosporine.
CarprofenCarprofen may increase the nephrotoxic activities of Cyclosporine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Cyclosporine.
CaspofunginThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.
CaspofunginThe serum concentration of Cyclosporine can be increased when it is combined with Caspofungin.
CastanospermineCastanospermine may increase the nephrotoxic activities of Cyclosporine.
CelecoxibCelecoxib may increase the nephrotoxic activities of Cyclosporine.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Cyclosporine.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Cyclosporine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Cyclosporine.
CeritinibThe serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Cyclosporine.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Cyclosporine.
CeruleninThe metabolism of Cyclosporine can be decreased when combined with Cerulenin.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cyclosporine.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Cyclosporine.
ChloramphenicolThe serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Cyclosporine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Cyclosporine.
ChloroquineThe serum concentration of Cyclosporine can be increased when it is combined with Chloroquine.
ChloroxineThe metabolism of Cyclosporine can be decreased when combined with Chloroxine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Cyclosporine.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.
ChlorpromazineThe serum concentration of Cyclosporine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Cyclosporine can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Cyclosporine.
ChlorprothixeneThe serum concentration of Cyclosporine can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Cyclosporine.
CholesterolThe serum concentration of Cyclosporine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Cyclosporine can be decreased when it is combined with Cholic Acid.
ChymostatinThe serum concentration of Cyclosporine can be increased when it is combined with Chymostatin.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Cyclosporine.
CiclopiroxThe metabolism of Cyclosporine can be decreased when combined with Ciclopirox.
CilastatinThe serum concentration of Cyclosporine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.
CilnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cilnidipine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Cyclosporine.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Cyclosporine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Cyclosporine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Cyclosporine.
CiprofibrateCyclosporine may increase the nephrotoxic activities of Ciprofibrate.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Cyclosporine.
CiprofloxacinThe serum concentration of Cyclosporine can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cyclosporine.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Cyclosporine.
CitalopramThe metabolism of Citalopram can be decreased when combined with Cyclosporine.
CitalopramThe serum concentration of Cyclosporine can be increased when it is combined with Citalopram.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Cyclosporine.
ClarithromycinThe serum concentration of Cyclosporine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Cyclosporine can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Cyclosporine.
ClobazamThe metabolism of Clobazam can be decreased when combined with Cyclosporine.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Cyclosporine.
ClofazimineThe serum concentration of Cyclosporine can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Cyclosporine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Cyclosporine.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Cyclosporine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Cyclosporine.
ClomipramineThe serum concentration of Cyclosporine can be increased when it is combined with Clomipramine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Cyclosporine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Cyclosporine.
ClonixinClonixin may increase the nephrotoxic activities of Cyclosporine.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Cyclosporine.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Cyclosporine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Cyclosporine.
ClotrimazoleThe metabolism of Cyclosporine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Cyclosporine.
CobicistatThe serum concentration of Cyclosporine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cyclosporine.
CocaineThe metabolism of Cocaine can be decreased when combined with Cyclosporine.
CodeineThe metabolism of Codeine can be decreased when combined with Cyclosporine.
ColchicineThe metabolism of Colchicine can be decreased when combined with Cyclosporine.
ColchicineThe serum concentration of Cyclosporine can be increased when it is combined with Colchicine.
ColesevelamThe serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.
ColforsinThe serum concentration of Cyclosporine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Cyclosporine can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Cyclosporine.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Cyclosporine.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Cyclosporine.
CrizotinibThe serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Cyclosporine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.
CyclophosphamideCyclophosphamide may increase the immunosuppressive activities of Cyclosporine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Cyclosporine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Cyclosporine.
D-LimoneneD-Limonene may increase the nephrotoxic activities of Cyclosporine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.
Dabigatran etexilateThe serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Cyclosporine.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Cyclosporine.
DaclatasvirThe serum concentration of Cyclosporine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Cyclosporine.
DactinomycinThe serum concentration of Cyclosporine can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Cyclosporine.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Cyclosporine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cyclosporine.
DarodipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Darodipine.
DarunavirThe serum concentration of Cyclosporine can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Cyclosporine.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Cyclosporine.
DasatinibThe serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Cyclosporine.
DaunorubicinDaunorubicin may increase the nephrotoxic activities of Cyclosporine.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Cyclosporine.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Cyclosporine.
Decanoic AcidThe metabolism of Cyclosporine can be decreased when combined with Decanoic Acid.
DeferasiroxThe serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Cyclosporine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Cyclosporine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclosporine.
DesipramineThe serum concentration of Cyclosporine can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Cyclosporine can be increased when it is combined with Desloratadine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.
DexamethasoneThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Cyclosporine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.
DextromethorphanThe serum concentration of Cyclosporine can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.
DiazepamThe metabolism of Diazepam can be decreased when combined with Cyclosporine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Cyclosporine.
DiclofenacThe serum concentration of Cyclosporine can be increased when it is combined with Diclofenac.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Cyclosporine.
DidanosineDidanosine can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cyclosporine.
DiflunisalDiflunisal may increase the nephrotoxic activities of Cyclosporine.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Cyclosporine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cyclosporine.
DigoxinThe serum concentration of Cyclosporine can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.
DihydroergotamineThe metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinDihydrostreptomycin may increase the nephrotoxic activities of Cyclosporine.
DihydrotestosteroneDihydrotestosterone may increase the hepatotoxic activities of Cyclosporine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Cyclosporine.
DiltiazemThe metabolism of Cyclosporine can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Cyclosporine.
DipyridamoleThe serum concentration of Cyclosporine can be increased when it is combined with Dipyridamole.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Cyclosporine.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Cyclosporine.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Cyclosporine.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Cyclosporine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cyclosporine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cyclosporine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Cyclosporine.
DopamineThe metabolism of Dopamine can be decreased when combined with Cyclosporine.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Cyclosporine.
DotarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dotarizine.
DoxazosinThe serum concentration of Cyclosporine can be increased when it is combined with Doxazosin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Cyclosporine.
DoxepinThe serum concentration of Cyclosporine can be increased when it is combined with Doxepin.
DoxorubicinDoxorubicin may increase the nephrotoxic activities of Cyclosporine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Cyclosporine.
DoxycyclineThe metabolism of Cyclosporine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Cyclosporine.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.
DronedaroneThe metabolism of Cyclosporine can be decreased when combined with Dronedarone.
DroxicamDroxicam may increase the nephrotoxic activities of Cyclosporine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Cyclosporine.
EcabetThe serum concentration of Cyclosporine can be increased when it is combined with Ecabet.
EconazoleThe metabolism of Cyclosporine can be decreased when combined with Econazole.
EdoxabanThe serum concentration of Cyclosporine can be increased when it is combined with Edoxaban.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Cyclosporine.
EfavirenzThe serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Cyclosporine.
EfinaconazoleThe metabolism of Cyclosporine can be decreased when combined with Efinaconazole.
EfonidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Efonidipine.
ElafinThe serum concentration of Cyclosporine can be increased when it is combined with Elafin.
ElbasvirThe serum concentration of Cyclosporine can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Cyclosporine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Cyclosporine.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Cyclosporine.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Cyclosporine.
EnalaprilThe serum concentration of Cyclosporine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Cyclosporine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Cyclosporine can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Cyclosporine.
EperisoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Eperisone.
EpinastineThe metabolism of Epinastine can be decreased when combined with Cyclosporine.
EpirizoleEpirizole may increase the nephrotoxic activities of Cyclosporine.
EpirubicinEpirubicin may increase the nephrotoxic activities of Cyclosporine.
EplerenoneEplerenone may increase the hyperkalemic activities of Cyclosporine.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Cyclosporine.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Cyclosporine.
EprosartanEprosartan may increase the hyperkalemic activities of Cyclosporine.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Cyclosporine.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Cyclosporine.
ErgonovineThe serum concentration of Cyclosporine can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Cyclosporine.
ErgotamineThe serum concentration of Cyclosporine can be increased when it is combined with Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Cyclosporine.
ErythromycinThe metabolism of Cyclosporine can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Cyclosporine.
Eslicarbazepine acetateThe serum concentration of Cyclosporine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Cyclosporine.
EstazolamThe metabolism of Estazolam can be decreased when combined with Cyclosporine.
EstradiolThe metabolism of Estradiol can be decreased when combined with Cyclosporine.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Cyclosporine.
EstramustineThe metabolism of Estramustine can be decreased when combined with Cyclosporine.
EstramustineThe serum concentration of Cyclosporine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Cyclosporine.
EstroneThe metabolism of Estrone can be decreased when combined with Cyclosporine.
EstroneThe serum concentration of Cyclosporine can be decreased when it is combined with Estrone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Cyclosporine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Cyclosporine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.
EtanerceptEtanercept may increase the nephrotoxic activities of Cyclosporine.
EthanolThe metabolism of Ethanol can be decreased when combined with Cyclosporine.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Cyclosporine.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Cyclosporine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.
EtodolacEtodolac may increase the nephrotoxic activities of Cyclosporine.
EtodolacThe metabolism of Etodolac can be decreased when combined with Cyclosporine.
EtofenamateEtofenamate may increase the nephrotoxic activities of Cyclosporine.
EtofibrateCyclosporine may increase the nephrotoxic activities of Etofibrate.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Cyclosporine.
EtoposideThe metabolism of Etoposide can be decreased when combined with Cyclosporine.
EtoposideThe serum concentration of Cyclosporine can be increased when it is combined with Etoposide.
EtoricoxibEtoricoxib may increase the nephrotoxic activities of Cyclosporine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Cyclosporine.
EtravirineThe serum concentration of Cyclosporine can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Cyclosporine.
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Cyclosporine.
EverolimusThe metabolism of Everolimus can be decreased when combined with Cyclosporine.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Cyclosporine.
exisulindexisulind may increase the nephrotoxic activities of Cyclosporine.
EzetimibeThe serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Cyclosporine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Cyclosporine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Cyclosporine.
FelodipineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.
FelodipineThe serum concentration of Cyclosporine can be increased when it is combined with Felodipine.
FenbufenFenbufen may increase the nephrotoxic activities of Cyclosporine.
FendilineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fendiline.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Cyclosporine.
FenoprofenFenoprofen may increase the nephrotoxic activities of Cyclosporine.
FentanylThe metabolism of Fentanyl can be decreased when combined with Cyclosporine.
FentanylThe serum concentration of Cyclosporine can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Cyclosporine.
FexofenadineThe serum concentration of Cyclosporine can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Cyclosporine.
FidaxomicinThe serum concentration of Cyclosporine can be increased when it is combined with Fidaxomicin.
FimasartanThe serum concentration of Fimasartan can be increased when it is combined with Cyclosporine.
FinasterideThe metabolism of Finasteride can be decreased when combined with Cyclosporine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Cyclosporine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Cyclosporine.
FloctafenineFloctafenine may increase the nephrotoxic activities of Cyclosporine.
FluconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.
FlucytosineThe metabolism of Cyclosporine can be decreased when combined with Flucytosine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Cyclosporine.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Cyclosporine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Cyclosporine.
FlunixinFlunixin may increase the nephrotoxic activities of Cyclosporine.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Cyclosporine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cyclosporine.
FluoxetineThe serum concentration of Cyclosporine can be increased when it is combined with Fluoxetine.
FluoxymesteroneFluoxymesterone may increase the hepatotoxic activities of Cyclosporine.
FlupentixolThe serum concentration of Cyclosporine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Cyclosporine can be increased when it is combined with Fluphenazine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Cyclosporine.
FlurazepamThe serum concentration of Cyclosporine can be increased when it is combined with Flurazepam.
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Cyclosporine.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Cyclosporine.
FlutamideThe metabolism of Flutamide can be decreased when combined with Cyclosporine.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Cyclosporine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Cyclosporine.
FluvoxamineThe metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.
ForasartanForasartan may increase the hyperkalemic activities of Cyclosporine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Cyclosporine.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Cyclosporine.
FosaprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the nephrotoxic activities of Cyclosporine.
FosinoprilThe serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.
FosphenytoinThe serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Cyclosporine.
FramycetinFramycetin may increase the nephrotoxic activities of Cyclosporine.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Cyclosporine.
FurosemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.
Fusidic AcidThe serum concentration of Cyclosporine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gabapentin.
GalantamineThe metabolism of Galantamine can be decreased when combined with Cyclosporine.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Cyclosporine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Cyclosporine.
GefitinibThe serum concentration of Cyclosporine can be increased when it is combined with Gefitinib.
GeldanamycinThe serum concentration of Cyclosporine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Cyclosporine.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Cyclosporine.
GenisteinThe serum concentration of Cyclosporine can be increased when it is combined with Genistein.
GentamicinGentamicin may increase the nephrotoxic activities of Cyclosporine.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Cyclosporine.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Cyclosporine.
GlipizideThe metabolism of Glipizide can be decreased when combined with Cyclosporine.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.
GlyburideThe serum concentration of Cyclosporine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Cyclosporine can be increased when it is combined with Glycerol.
GlyphosateThe metabolism of Cyclosporine can be decreased when combined with Glyphosate.
GM6001The serum concentration of Cyclosporine can be increased when it is combined with GM6001.
Gramicidin DThe serum concentration of Cyclosporine can be increased when it is combined with Gramicidin D.
GranisetronThe metabolism of Granisetron can be decreased when combined with Cyclosporine.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Cyclosporine.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Cyclosporine.
GrepafloxacinThe serum concentration of Cyclosporine can be increased when it is combined with Grepafloxacin.
GriseofulvinThe serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Cyclosporine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Cyclosporine.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Cyclosporine.
HaloperidolThe serum concentration of Cyclosporine can be increased when it is combined with Haloperidol.
HaloproginThe metabolism of Cyclosporine can be decreased when combined with Haloprogin.
HalothaneThe metabolism of Halothane can be decreased when combined with Cyclosporine.
HexetidineThe metabolism of Cyclosporine can be decreased when combined with Hexetidine.
HexobarbitalThe metabolism of Cyclosporine can be increased when combined with Hexobarbital.
HirulogThe serum concentration of Cyclosporine can be increased when it is combined with Hirulog.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Cyclosporine.
HMPL-004HMPL-004 may increase the nephrotoxic activities of Cyclosporine.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.
HydrocortisoneThe serum concentration of Cyclosporine can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Cyclosporine.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Cyclosporine.
Hygromycin BHygromycin B may increase the nephrotoxic activities of Cyclosporine.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.
IbuprofenIbuprofen may increase the nephrotoxic activities of Cyclosporine.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Cyclosporine.
IbuproxamIbuproxam may increase the nephrotoxic activities of Cyclosporine.
IcatibantIcatibant may increase the nephrotoxic activities of Cyclosporine.
IdarubicinIdarubicin may increase the nephrotoxic activities of Cyclosporine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Cyclosporine.
IdelalisibThe serum concentration of Cyclosporine can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Cyclosporine.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cyclosporine resulting in a loss in efficacy.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Cyclosporine.
ImatinibThe serum concentration of Cyclosporine can be increased when it is combined with Imatinib.
ImipenemCyclosporine may increase the neurotoxic activities of Imipenem.
ImipramineThe metabolism of Imipramine can be decreased when combined with Cyclosporine.
ImipramineThe serum concentration of Cyclosporine can be increased when it is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Cyclosporine.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Cyclosporine.
IndapamideThe metabolism of Indapamide can be decreased when combined with Cyclosporine.
IndinavirThe metabolism of Indinavir can be decreased when combined with Cyclosporine.
IndinavirThe serum concentration of Cyclosporine can be decreased when it is combined with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Cyclosporine.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Cyclosporine.
IndomethacinThe serum concentration of Cyclosporine can be increased when it is combined with Indomethacin.
IndoprofenIndoprofen may increase the nephrotoxic activities of Cyclosporine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.
IrbesartanIrbesartan may increase the hyperkalemic activities of Cyclosporine.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Cyclosporine.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Cyclosporine.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Cyclosporine.
IsoconazoleThe metabolism of Cyclosporine can be decreased when combined with Isoconazole.
IsoflurophateThe serum concentration of Cyclosporine can be increased when it is combined with Isoflurophate.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.
IsoxicamIsoxicam may increase the nephrotoxic activities of Cyclosporine.
IsradipineThe metabolism of Cyclosporine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Cyclosporine.
ItraconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Cyclosporine.
IvacaftorThe serum concentration of Cyclosporine can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Cyclosporine.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Cyclosporine.
IvermectinThe serum concentration of Cyclosporine can be increased when it is combined with Ivermectin.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Cyclosporine.
IxazomibThe serum concentration of Cyclosporine can be increased when it is combined with Ixazomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Cyclosporine.
KanamycinKanamycin may increase the nephrotoxic activities of Cyclosporine.
KebuzoneKebuzone may increase the nephrotoxic activities of Cyclosporine.
KetamineThe metabolism of Ketamine can be decreased when combined with Cyclosporine.
KetamineThe serum concentration of Cyclosporine can be increased when it is combined with Ketamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Cyclosporine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Cyclosporine.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Cyclosporine.
KetoconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may increase the nephrotoxic activities of Cyclosporine.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Cyclosporine.
KetorolacKetorolac may increase the nephrotoxic activities of Cyclosporine.
LacidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lacidipine.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Cyclosporine.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Cyclosporine.
LanreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Cyclosporine.
LansoprazoleThe serum concentration of Cyclosporine can be increased when it is combined with Lansoprazole.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Cyclosporine.
LapatinibThe serum concentration of Cyclosporine can be increased when it is combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Cyclosporine.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Cyclosporine.
LeflunomideLeflunomide may increase the nephrotoxic activities of Cyclosporine.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Cyclosporine.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Cyclosporine.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Cyclosporine.
LepirudinThe serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.
LercanidipineThe serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Cyclosporine.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Cyclosporine.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Cyclosporine.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Cyclosporine.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Cyclosporine.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Cyclosporine.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Cyclosporine.
LevofloxacinThe serum concentration of Cyclosporine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Cyclosporine.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Cyclosporine.
LevothyroxineThe serum concentration of Cyclosporine can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Cyclosporine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Cyclosporine.
LidocaineThe serum concentration of Cyclosporine can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Cyclosporine.
LiothyronineThe serum concentration of Cyclosporine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Cyclosporine can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Cyclosporine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Cyclosporine.
LoperamideThe serum concentration of Cyclosporine can be increased when it is combined with Loperamide.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Cyclosporine.
LopinavirThe serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Cyclosporine.
LoratadineThe serum concentration of Cyclosporine can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cyclosporine.
LornoxicamLornoxicam may increase the nephrotoxic activities of Cyclosporine.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Cyclosporine.
LosartanThe metabolism of Losartan can be decreased when combined with Cyclosporine.
LosartanLosartan may increase the hyperkalemic activities of Cyclosporine.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.
LovastatinThe metabolism of Cyclosporine can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Cyclosporine.
LuliconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Cyclosporine.
LumiracoxibLumiracoxib may increase the nephrotoxic activities of Cyclosporine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Cyclosporine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Cyclosporine.
MacitentanThe metabolism of Macitentan can be decreased when combined with Cyclosporine.
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Cyclosporine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Sulfate.
ManidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Manidipine.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Cyclosporine.
MaprotilineThe serum concentration of Cyclosporine can be increased when it is combined with Maprotiline.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Cyclosporine.
MasoprocolMasoprocol may increase the nephrotoxic activities of Cyclosporine.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Cyclosporine.
MebendazoleThe serum concentration of Cyclosporine can be increased when it is combined with Mebendazole.
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Cyclosporine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Cyclosporine.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Cyclosporine.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Cyclosporine.
MefloquineThe serum concentration of Cyclosporine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Cyclosporine can be increased when it is combined with Megestrol acetate.
MelatoninThe metabolism of Melatonin can be decreased when combined with Cyclosporine.
MeloxicamMeloxicam may increase the nephrotoxic activities of Cyclosporine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Cyclosporine.
MelphalanMelphalan may increase the nephrotoxic activities of Cyclosporine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Cyclosporine.
MeprobamateThe serum concentration of Cyclosporine can be increased when it is combined with Meprobamate.
MesalazineMesalazine may increase the nephrotoxic activities of Cyclosporine.
MestranolThe metabolism of Mestranol can be decreased when combined with Cyclosporine.
MetamizoleMetamizole may increase the nephrotoxic activities of Cyclosporine.
MethadoneThe metabolism of Methadone can be decreased when combined with Cyclosporine.
MethadoneThe serum concentration of Cyclosporine can be increased when it is combined with Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Cyclosporine.
MethohexitalThe metabolism of Cyclosporine can be increased when combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Cyclosporine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Cyclosporine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.
MethylphenobarbitalThe metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.
MethyltestosteroneMethyltestosterone may increase the hepatotoxic activities of Cyclosporine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Cyclosporine.
MetoclopramideMetoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Cyclosporine.
MetoprololThe serum concentration of Cyclosporine can be increased when it is combined with Metoprolol.
MetreleptinThe serum concentration of Cyclosporine can be decreased when it is combined with Metreleptin.
MetrizamideMetrizamide may increase the nephrotoxic activities of Cyclosporine.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Cyclosporine.
MevastatinThe metabolism of Cyclosporine can be decreased when combined with Mevastatin.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cyclosporine.
MianserinThe metabolism of Mianserin can be decreased when combined with Cyclosporine.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Cyclosporine.
MibefradilThe serum concentration of Cyclosporine can be increased when it is combined with Mibefradil.
MicafunginThe metabolism of Cyclosporine can be decreased when combined with Micafungin.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Cyclosporine.
MiconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Miconazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Cyclosporine.
MidazolamThe serum concentration of Cyclosporine can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Cyclosporine.
MiltefosineThe metabolism of Cyclosporine can be decreased when combined with Miltefosine.
MinoxidilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Minoxidil.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Cyclosporine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Cyclosporine.
MitomycinThe serum concentration of Cyclosporine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Cyclosporine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Cyclosporine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cyclosporine.
ModafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Cyclosporine.
MoexiprilThe serum concentration of Cyclosporine can be increased when it is combined with Moexipril.
MonensinThe metabolism of Cyclosporine can be decreased when combined with Monensin.
MontelukastThe metabolism of Montelukast can be decreased when combined with Cyclosporine.
MorphineThe metabolism of Morphine can be decreased when combined with Cyclosporine.
MorphineThe serum concentration of Cyclosporine can be increased when it is combined with Morphine.
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Cyclosporine.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Cyclosporine.
MyxothiazolThe metabolism of Cyclosporine can be decreased when combined with Myxothiazol.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cyclosporine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabumetoneNabumetone may increase the nephrotoxic activities of Cyclosporine.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Cyclosporine.
NafcillinThe metabolism of Cyclosporine can be increased when combined with Nafcillin.
NaftifineNaftifine may increase the nephrotoxic activities of Cyclosporine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cyclosporine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Cyclosporine.
NaltrexoneThe serum concentration of Cyclosporine can be increased when it is combined with Naltrexone.
NaproxenNaproxen may increase the nephrotoxic activities of Cyclosporine.
NaproxenThe metabolism of Naproxen can be decreased when combined with Cyclosporine.
NaringeninThe serum concentration of Cyclosporine can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.
NatamycinThe metabolism of Cyclosporine can be decreased when combined with Natamycin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cyclosporine.
NCX 4016NCX 4016 may increase the nephrotoxic activities of Cyclosporine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Cyclosporine.
NefazodoneThe serum concentration of Cyclosporine can be decreased when it is combined with Nefazodone.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Cyclosporine.
NelfinavirThe serum concentration of Cyclosporine can be decreased when it is combined with Nelfinavir.
NeomycinNeomycin may increase the nephrotoxic activities of Cyclosporine.
NeostigmineThe serum concentration of Cyclosporine can be increased when it is combined with Neostigmine.
NepafenacNepafenac may increase the nephrotoxic activities of Cyclosporine.
NetilmicinNetilmicin may increase the nephrotoxic activities of Cyclosporine.
NetupitantThe serum concentration of Cyclosporine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Cyclosporine.
NevirapineThe metabolism of Cyclosporine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Cyclosporine.
NicardipineThe serum concentration of Cyclosporine can be increased when it is combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Cyclosporine.
NicotineThe metabolism of Nicotine can be decreased when combined with Cyclosporine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Cyclosporine.
NifedipineThe serum concentration of Cyclosporine can be decreased when it is combined with Nifedipine.
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Cyclosporine.
NiguldipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Niguldipine.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Cyclosporine.
NiludipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Niludipine.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Cyclosporine.
NimesulideNimesulide may increase the nephrotoxic activities of Cyclosporine.
NimesulideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nimesulide.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Cyclosporine.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.
NisoldipineThe serum concentration of Cyclosporine can be increased when it is combined with Nisoldipine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Cyclosporine.
NitrazepamThe serum concentration of Cyclosporine can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Cyclosporine.
NitrendipineThe serum concentration of Cyclosporine can be increased when it is combined with Nitrendipine.
NitroxolineThe metabolism of Cyclosporine can be decreased when combined with Nitroxoline.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Cyclosporine.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Cyclosporine.
NorethisteroneThe serum concentration of Cyclosporine can be decreased when it is combined with Norethisterone.
NorfloxacinThe metabolism of Cyclosporine can be decreased when combined with Norfloxacin.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Cyclosporine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Cyclosporine.
NystatinThe metabolism of Cyclosporine can be decreased when combined with Nystatin.
OctreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Cyclosporine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Cyclosporine.
OlaparibThe metabolism of Cyclosporine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hyperkalemic activities of Cyclosporine.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Cyclosporine.
OlopatadineOlopatadine may increase the nephrotoxic activities of Cyclosporine.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Cyclosporine.
OlsalazineOlsalazine may increase the nephrotoxic activities of Cyclosporine.
OmapatrilatThe serum concentration of Cyclosporine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Cyclosporine.
OmeprazoleThe serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Cyclosporine.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Cyclosporine.
OrgoteinOrgotein may increase the nephrotoxic activities of Cyclosporine.
OrlistatThe serum concentration of Cyclosporine can be decreased when it is combined with Orlistat.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Cyclosporine.
OsimertinibThe serum concentration of Cyclosporine can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Cyclosporine.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Cyclosporine.
OtamixabanThe serum concentration of Cyclosporine can be increased when it is combined with Otamixaban.
OxandroloneOxandrolone may increase the hepatotoxic activities of Cyclosporine.
OxaprozinOxaprozin may increase the nephrotoxic activities of Cyclosporine.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Cyclosporine.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Cyclosporine.
OxiconazoleThe metabolism of Cyclosporine can be decreased when combined with Oxiconazole.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Cyclosporine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Cyclosporine.
OxymetholoneOxymetholone may increase the hepatotoxic activities of Cyclosporine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Cyclosporine.
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Cyclosporine.
P-NitrophenolThe serum concentration of Cyclosporine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Cyclosporine.
PaclitaxelThe serum concentration of Cyclosporine can be increased when it is combined with Paclitaxel.
pafuramidineThe metabolism of Cyclosporine can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Cyclosporine.
Palmitic AcidThe serum concentration of Cyclosporine can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cyclosporine.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Cyclosporine.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Cyclosporine.
PantoprazoleThe serum concentration of Cyclosporine can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Cyclosporine.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Cyclosporine.
ParecoxibParecoxib may increase the nephrotoxic activities of Cyclosporine.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Cyclosporine.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Cyclosporine.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Cyclosporine.
ParomomycinParomomycin may increase the nephrotoxic activities of Cyclosporine.
ParoxetineThe serum concentration of Cyclosporine can be increased when it is combined with Paroxetine.
PasireotideThe serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.
PentamidineThe metabolism of Cyclosporine can be decreased when combined with Pentamidine.
PentobarbitalThe metabolism of Cyclosporine can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Cyclosporine.
PergolideThe metabolism of Pergolide can be decreased when combined with Cyclosporine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Cyclosporine.
PerindoprilThe serum concentration of Cyclosporine can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Cyclosporine.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Cyclosporine.
PethidineThe metabolism of Pethidine can be decreased when combined with Cyclosporine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cyclosporine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Cyclosporine.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Cyclosporine.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Cyclosporine.
PhenytoinThe metabolism of Cyclosporine can be increased when combined with Phenytoin.
PhosphoramidonThe serum concentration of Cyclosporine can be increased when it is combined with Phosphoramidon.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Cyclosporine.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Cyclosporine.
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Cyclosporine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cyclosporine.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Cyclosporine.
PinaveriumThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pinaverium.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Cyclosporine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Cyclosporine.
PiretanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.
PirfenidonePirfenidone may increase the nephrotoxic activities of Cyclosporine.
PiroxicamPiroxicam may increase the nephrotoxic activities of Cyclosporine.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Cyclosporine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.
Platelet Activating FactorThe serum concentration of Cyclosporine can be decreased when it is combined with Platelet Activating Factor.
PlicamycinPlicamycin may increase the nephrotoxic activities of Cyclosporine.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Cyclosporine.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Cyclosporine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Cyclosporine.
PonatinibThe serum concentration of Cyclosporine can be increased when it is combined with Ponatinib.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Cyclosporine.
PosaconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Posaconazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Cyclosporine.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Cyclosporine.
PravastatinThe serum concentration of Cyclosporine can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Cyclosporine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Cyclosporine.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Cyclosporine.
PrazosinThe serum concentration of Cyclosporine can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Cyclosporine.
PrednisoneThe serum concentration of the active metabolites of Prednisone can be increased when Prednisone is used in combination with Cyclosporine.
PrednisoneThe serum concentration of Cyclosporine can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pregabalin.
PrenylamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Prenylamine.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Cyclosporine.
PrimidoneThe metabolism of Cyclosporine can be increased when combined with Primidone.
PrinomastatThe serum concentration of Cyclosporine can be increased when it is combined with Prinomastat.
ProbenecidThe serum concentration of Cyclosporine can be increased when it is combined with Probenecid.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cyclosporine.
ProgesteroneThe serum concentration of Cyclosporine can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Cyclosporine.
PromazineThe metabolism of Promazine can be decreased when combined with Cyclosporine.
PromethazineThe serum concentration of Cyclosporine can be increased when it is combined with Promethazine.
PropacetamolPropacetamol may increase the nephrotoxic activities of Cyclosporine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cyclosporine.
PropofolThe metabolism of Propofol can be decreased when combined with Cyclosporine.
PropranololThe metabolism of Propranolol can be decreased when combined with Cyclosporine.
PropranololThe serum concentration of Cyclosporine can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Cyclosporine can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.
PTC299PTC299 may increase the nephrotoxic activities of Cyclosporine.
PuromycinPuromycin may increase the nephrotoxic activities of Cyclosporine.
PyrazinamideThe serum concentration of Cyclosporine can be increased when it is combined with Pyrazinamide.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Cyclosporine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Cyclosporine.
QuercetinThe serum concentration of Cyclosporine can be increased when it is combined with Quercetin.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Cyclosporine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Cyclosporine.
QuinacrineThe serum concentration of Cyclosporine can be increased when it is combined with Quinacrine.
QuinaprilThe serum concentration of Cyclosporine can be increased when it is combined with Quinapril.
QuinidineThe metabolism of Quinidine can be decreased when combined with Cyclosporine.
QuinidineThe serum concentration of Cyclosporine can be increased when it is combined with Quinidine.
QuinineThe metabolism of Quinine can be decreased when combined with Cyclosporine.
QuinineThe serum concentration of Cyclosporine can be increased when it is combined with Quinine.
QuinupristinThe serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Cyclosporine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rabies vaccine.
RadicicolThe metabolism of Cyclosporine can be decreased when combined with Radicicol.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Cyclosporine.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Cyclosporine.
RamiprilThe serum concentration of Cyclosporine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Cyclosporine.
RanitidineThe serum concentration of Cyclosporine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Cyclosporine can be increased when it is combined with Ranolazine.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Cyclosporine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Cyclosporine.
ReboxetineThe serum concentration of Cyclosporine can be increased when it is combined with Reboxetine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Cyclosporine.
RegorafenibThe serum concentration of Cyclosporine can be increased when it is combined with Regorafenib.
RemikirenThe serum concentration of Cyclosporine can be increased when it is combined with Remikiren.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.
ReserpineThe serum concentration of Cyclosporine can be decreased when it is combined with Reserpine.
ResveratrolResveratrol may increase the nephrotoxic activities of Cyclosporine.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Cyclosporine.
RibostamycinRibostamycin may increase the nephrotoxic activities of Cyclosporine.
RifabutinThe metabolism of Cyclosporine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Cyclosporine.
RifampicinThe serum concentration of Cyclosporine can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Cyclosporine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Cyclosporine.
RilpivirineThe serum concentration of Cyclosporine can be increased when it is combined with Rilpivirine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Cyclosporine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Cyclosporine.
RisedronateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Cyclosporine.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Cyclosporine.
RitonavirThe serum concentration of Cyclosporine can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.
RofecoxibRofecoxib may increase the nephrotoxic activities of Cyclosporine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Cyclosporine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Cyclosporine.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Cyclosporine.
RolapitantThe serum concentration of Cyclosporine can be increased when it is combined with Rolapitant.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Cyclosporine.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Cyclosporine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Cyclosporine.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Cyclosporine.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Cyclosporine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Cyclosporine.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Cyclosporine.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Cyclosporine.
SalicylamideSalicylamide may increase the nephrotoxic activities of Cyclosporine.
Salicylhydroxamic AcidThe metabolism of Cyclosporine can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Cyclosporine.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Cyclosporine.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Cyclosporine.
SalsalateSalsalate may increase the nephrotoxic activities of Cyclosporine.
SaprisartanSaprisartan may increase the hyperkalemic activities of Cyclosporine.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Cyclosporine.
SaquinavirThe serum concentration of Cyclosporine can be decreased when it is combined with Saquinavir.
SaralasinSaralasin may increase the hyperkalemic activities of Cyclosporine.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Cyclosporine.
ScopolamineThe serum concentration of Cyclosporine can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Cyclosporine can be increased when combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Cyclosporine.
SelegilineThe serum concentration of Cyclosporine can be increased when it is combined with Selegiline.
SelexipagThe metabolism of Selexipag can be decreased when combined with Cyclosporine.
SeratrodastSeratrodast may increase the nephrotoxic activities of Cyclosporine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Cyclosporine.
SertaconazoleThe metabolism of Cyclosporine can be decreased when combined with Sertaconazole.
SertindoleThe metabolism of Sertindole can be decreased when combined with Cyclosporine.
SertralineThe metabolism of Sertraline can be decreased when combined with Cyclosporine.
SertralineThe serum concentration of Cyclosporine can be increased when it is combined with Sertraline.
SevelamerThe serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Cyclosporine.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Cyclosporine.
SildenafilThe metabolism of Cyclosporine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.
SiltuximabThe serum concentration of Cyclosporine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.
SinefunginThe metabolism of Cyclosporine can be decreased when combined with Sinefungin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Cyclosporine.
SirolimusThe serum concentration of Cyclosporine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Cyclosporine.
SitaxentanThe serum concentration of Sitaxentan can be increased when it is combined with Cyclosporine.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cyclosporine.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Cyclosporine.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Cyclosporine.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Cyclosporine.
SorafenibThe serum concentration of Cyclosporine can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Cyclosporine.
SpectinomycinSpectinomycin may increase the nephrotoxic activities of Cyclosporine.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Cyclosporine.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Cyclosporine.
SpiraprilThe serum concentration of Cyclosporine can be increased when it is combined with Spirapril.
SpironolactoneSpironolactone may increase the hyperkalemic activities of Cyclosporine.
SRT501SRT501 may increase the nephrotoxic activities of Cyclosporine.
St. John's WortThe serum concentration of Cyclosporine can be decreased when it is combined with St. John's Wort.
StanozololStanozolol may increase the hepatotoxic activities of Cyclosporine.
StaurosporineThe serum concentration of Cyclosporine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Cyclosporine can be increased when it is combined with Stiripentol.
StreptomycinStreptomycin may increase the nephrotoxic activities of Cyclosporine.
StreptozocinStreptozocin may increase the nephrotoxic activities of Cyclosporine.
SucralfateSucralfate can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Cyclosporine.
SulconazoleThe metabolism of Cyclosporine can be decreased when combined with Sulconazole.
SulfadiazineSulfadiazine may increase the nephrotoxic activities of Cyclosporine.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Cyclosporine.
SulfamethoxazoleSulfamethoxazole may increase the nephrotoxic activities of Cyclosporine.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Cyclosporine.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Cyclosporine.
SulfasalazineSulfasalazine may increase the nephrotoxic activities of Cyclosporine.
SulfinpyrazoneThe serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Cyclosporine.
SulfisoxazoleSulfisoxazole may increase the nephrotoxic activities of Cyclosporine.
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Cyclosporine.
SulindacSulindac may increase the nephrotoxic activities of Cyclosporine.
SumatriptanThe serum concentration of Cyclosporine can be increased when it is combined with Sumatriptan.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Cyclosporine.
SunitinibThe serum concentration of Cyclosporine can be increased when it is combined with Sunitinib.
SuprofenSuprofen may increase the nephrotoxic activities of Cyclosporine.
SuprofenThe metabolism of Suprofen can be decreased when combined with Cyclosporine.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Cyclosporine.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Cyclosporine.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cyclosporine.
TacrineThe serum concentration of Cyclosporine can be increased when it is combined with Tacrine.
TacrolimusTacrolimus may increase the nephrotoxic activities of Cyclosporine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cyclosporine.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Cyclosporine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Cyclosporine.
TamoxifenThe serum concentration of Cyclosporine can be decreased when it is combined with Tamoxifen.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Cyclosporine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Cyclosporine.
TasosartanTasosartan may increase the hyperkalemic activities of Cyclosporine.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Cyclosporine.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Cyclosporine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Cyclosporine.
Taurocholic AcidThe serum concentration of Cyclosporine can be increased when it is combined with Taurocholic Acid.
TavaboroleThe metabolism of Cyclosporine can be decreased when combined with Tavaborole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Cyclosporine.
TelaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Cyclosporine.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Cyclosporine.
TelmisartanTelmisartan may increase the hyperkalemic activities of Cyclosporine.
TemazepamThe metabolism of Temazepam can be decreased when combined with Cyclosporine.
TemocaprilThe serum concentration of Cyclosporine can be increased when it is combined with Temocapril.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Cyclosporine.
TemsirolimusThe serum concentration of Cyclosporine can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Cyclosporine.
TenoxicamTenoxicam may increase the nephrotoxic activities of Cyclosporine.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Cyclosporine.
TepoxalinTepoxalin may increase the nephrotoxic activities of Cyclosporine.
TerazosinThe serum concentration of Cyclosporine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Cyclosporine can be decreased when combined with Terbinafine.
TerconazoleThe metabolism of Cyclosporine can be decreased when combined with Terconazole.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Cyclosporine.
TerfenadineThe serum concentration of Cyclosporine can be increased when it is combined with Terfenadine.
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Cyclosporine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Cyclosporine.
TesmilifeneThe serum concentration of Cyclosporine can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Cyclosporine.
TestosteroneThe serum concentration of Cyclosporine can be increased when it is combined with Testosterone.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Cyclosporine.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Cyclosporine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cyclosporine.
ThiamylalThe metabolism of Cyclosporine can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Cyclosporine can be increased when combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cyclosporine.
ThiorphanThe serum concentration of Cyclosporine can be increased when it is combined with Thiorphan.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Cyclosporine.
ThymolThe metabolism of Cyclosporine can be decreased when combined with Thymol.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Cyclosporine.
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Cyclosporine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.
TiclopidineThe metabolism of Cyclosporine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Cyclosporine.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Cyclosporine.
TioconazoleThe metabolism of Cyclosporine can be decreased when combined with Tioconazole.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cyclosporine.
TipranavirThe serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Cyclosporine.
TobramycinTobramycin may increase the nephrotoxic activities of Cyclosporine.
TocilizumabThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.
TofacitinibCyclosporine may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Cyclosporine.
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Cyclosporine.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tolfenamic Acid.
TolmetinTolmetin may increase the nephrotoxic activities of Cyclosporine.
TolnaftateThe metabolism of Cyclosporine can be decreased when combined with Tolnaftate.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cyclosporine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cyclosporine.
TorasemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Cyclosporine.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Cyclosporine.
TramadolThe metabolism of Tramadol can be decreased when combined with Cyclosporine.
TrandolaprilThe serum concentration of Cyclosporine can be increased when it is combined with Trandolapril.
TranilastTranilast may increase the nephrotoxic activities of Cyclosporine.
TranilastThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tranilast.
TrastuzumabTrastuzumab may increase the neutropenic activities of Cyclosporine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Cyclosporine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Cyclosporine.
TrazodoneThe serum concentration of Cyclosporine can be decreased when it is combined with Trazodone.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Cyclosporine.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Cyclosporine.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Cyclosporine.
TriamtereneTriamterene may increase the hyperkalemic activities of Cyclosporine.
TriazolamThe metabolism of Triazolam can be decreased when combined with Cyclosporine.
TrifluoperazineThe serum concentration of Cyclosporine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Cyclosporine can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Cyclosporine.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Cyclosporine.
TrimethoprimThe serum concentration of Cyclosporine can be decreased when it is combined with Trimethoprim.
TrimetrexateThe metabolism of Cyclosporine can be decreased when combined with Trimetrexate.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Cyclosporine.
TrimipramineThe serum concentration of Cyclosporine can be increased when it is combined with Trimipramine.
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Cyclosporine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Cyclosporine.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Cyclosporine.
TroleandomycinThe serum concentration of Cyclosporine can be increased when it is combined with Troleandomycin.
UbenimexThe serum concentration of Cyclosporine can be increased when it is combined with Ubenimex.
UdenafilThe metabolism of Udenafil can be decreased when combined with Cyclosporine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cyclosporine.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Cyclosporine.
ValdecoxibValdecoxib may increase the nephrotoxic activities of Cyclosporine.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Cyclosporine.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Cyclosporine.
ValsartanValsartan may increase the hyperkalemic activities of Cyclosporine.
ValsartanThe metabolism of Valsartan can be decreased when combined with Cyclosporine.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Cyclosporine.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Cyclosporine.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Cyclosporine.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Cyclosporine.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Cyclosporine.
VenlafaxineThe metabolism of Cyclosporine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Verapamil can be decreased when combined with Cyclosporine.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Cyclosporine.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Cyclosporine.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Cyclosporine.
VildagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Vildagliptin.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Cyclosporine.
VinblastineThe serum concentration of Cyclosporine can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cyclosporine.
VincristineThe serum concentration of Cyclosporine can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Cyclosporine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Cyclosporine.
VinorelbineThe serum concentration of Cyclosporine can be increased when it is combined with Vinorelbine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Cyclosporine.
Vitamin CThe serum concentration of Cyclosporine can be decreased when it is combined with Vitamin C.
Vitamin EThe serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.
VoriconazoleThe metabolism of Cyclosporine can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Cyclosporine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Cyclosporine.
XimelagatranThe serum concentration of Cyclosporine can be increased when it is combined with Ximelagatran.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Cyclosporine.
XylometazolineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Cyclosporine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Cyclosporine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cyclosporine.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Cyclosporine.
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Cyclosporine.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Cyclosporine.
ZiconotideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Cyclosporine.
ZileutonZileuton may increase the nephrotoxic activities of Cyclosporine.
ZileutonThe metabolism of Zileuton can be decreased when combined with Cyclosporine.
ZimelidineThe serum concentration of Cyclosporine can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Cyclosporine can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Cyclosporine.
ZomepiracZomepirac may increase the nephrotoxic activities of Cyclosporine.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Cyclosporine.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Cyclosporine.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Cyclosporine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.
Food Interactions
  • Avoid salt substitutes containing potassium.
  • Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.
  • Red wine may reduce cyclosporine levels due to increased metabolism, therefore it appears prudent to avoid red wine (white wine does not appear to affect cyclosporine metabolism).
  • When taken with a meal, AUC and Cmax of cyclosporine modified decreased.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Not Available
Specific Function:
Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B.
Gene Name:
CAMLG
Uniprot ID:
P49069
Molecular Weight:
32952.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M: Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS One. 2010 Sep 28;5(9). pii: e13008. doi: 10.1371/journal.pone.0013008. [PubMed:20927389 ]
  4. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565 ]
  5. Galat A, Bua J: Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010 Oct;67(20):3467-88. doi: 10.1007/s00018-010-0437-0. Epub 2010 Jul 4. [PubMed:20602248 ]
  6. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Calcium ion binding
Specific Function:
Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity (By similarity).
Gene Name:
PPP3R2
Uniprot ID:
Q96LZ3
Molecular Weight:
19533.065 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Virion binding
Specific Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
Gene Name:
PPIA
Uniprot ID:
P62937
Molecular Weight:
18012.42 Da
References
  1. Keckesova Z, Ylinen LM, Towers GJ: Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol. 2006 May;80(10):4683-90. [PubMed:16641261 ]
  2. Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM: The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11393-8. Epub 2006 Jul 18. [PubMed:16849427 ]
  3. Redell JB, Zhao J, Dash PK: Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation. J Neurosci Res. 2007 Jul;85(9):1980-8. [PubMed:17461417 ]
  4. Schaller T, Ylinen LM, Webb BL, Singh S, Towers GJ: Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol. 2007 Sep;81(18):10055-63. Epub 2007 Jul 3. [PubMed:17609268 ]
  5. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127 ]
  6. Stegmann CM, Luhrmann R, Wahl MC: The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein. PLoS One. 2010 Apr 2;5(4):e10013. doi: 10.1371/journal.pone.0010013. [PubMed:20368803 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Peptidyl-prolyl cis-trans isomerase activity
Specific Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Involved in regulation of the mitochondrial permeability transition pore (mPTP). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosi...
Gene Name:
PPIF
Uniprot ID:
P30405
Molecular Weight:
22040.09 Da
References
  1. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984 Nov 2;226(4674):544-7. [PubMed:6238408 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  3. Tiberghien F, Kurome T, Takesako K, Didier A, Wenandy T, Loor F: Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem. 2000 Jun 29;43(13):2547-56. [PubMed:10891114 ]
  4. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287 ]
  5. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  6. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143 ]
  7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  8. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  9. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. [PubMed:12604693 ]
  10. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153 ]
  11. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  12. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol. 2003 Sep;285(3):C584-91. Epub 2003 Apr 30. [PubMed:12724138 ]
  13. Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15. [PubMed:12975485 ]
  14. Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A: Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L. Bioorg Med Chem. 2003 Nov 17;11(23):5221-7. [PubMed:14604686 ]
  15. Rao US, Scarborough GA: Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol. 1994 Apr;45(4):773-6. [PubMed:7514263 ]
  16. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059 ]
  17. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004 ]
  18. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363 ]
  19. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409 ]
  20. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8. [PubMed:9914792 ]
  21. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141 ]
  22. Wigler PW: PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun. 1999 Apr 13;257(2):410-3. [PubMed:10198227 ]
  23. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH: Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310-8. [PubMed:10604964 ]
  24. Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9. [PubMed:14744620 ]
  25. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. [PubMed:15023456 ]
  26. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753 ]
  27. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  28. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  29. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439 ]
  30. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  31. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  32. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  33. Seeballuck F, Ashford MB, O'Driscoll CM: The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res. 2003 Jul;20(7):1085-92. [PubMed:12880295 ]
  34. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  35. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80. [PubMed:7681059 ]
  36. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 Aug;118(7):1841-7. [PubMed:8842452 ]
  37. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997 Sep;62(3):248-60. [PubMed:9333100 ]
  38. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700 ]
  39. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
  3. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. [PubMed:11343252 ]
  4. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
  5. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. [PubMed:10648470 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Pec MK, Aguirre A, Fernandez JJ, Souto ML, Dorta JF, Villar J: Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002 Nov;10(5):605-8. [PubMed:12373300 ]
  2. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994 Nov 11;269(45):27807-10. [PubMed:7961706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Bile acid:sodium symporter activity
Specific Function:
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
Gene Name:
SLC10A2
Uniprot ID:
Q12908
Molecular Weight:
37713.405 Da
References
  1. Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. [PubMed:9458785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sweet DH, Wolff NA, Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem. 1997 Nov 28;272(48):30088-95. [PubMed:9374486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  3. Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, Keppler D: Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90. [PubMed:10421658 ]
  4. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. [PubMed:10570049 ]
  5. Horikawa M, Kato Y, Tyson CA, Sugiyama Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23-33. [PubMed:15618649 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595 ]
  2. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003 Feb;304(2):610-6. [PubMed:12538813 ]
  3. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759 ]
  4. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. [PubMed:14530907 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:16